Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
13 studies found for:    GATA6
Show Display Options
Rank Status Study
1 Active, not recruiting Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Condition: Familial Adenomatous Polyposis
Interventions: Drug: Celecoxib;   Procedure: Colonoscopy Biopsy
2 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
3 Completed Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome
Condition: Irritable Bowel Disease
Interventions: Dietary Supplement: Soy isoflavones;   Dietary Supplement: cholecalciferol;   Dietary Supplement: Placebo of soy isoflavones;   Dietary Supplement: placebo of cholecalciferol
4 Completed Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects
Condition: Asthma
Interventions: Drug: SB010;   Drug: Placebo
5 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Conditions: GATA2;   Immunodeficiency;   MDS
Interventions: Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
6 Completed Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma
Condition: Asthma
Interventions: Drug: SB010;   Drug: Placebo
7 Completed Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects
Condition: Asthma
Interventions: Drug: SB010;   Drug: Placebo (phosphate-buffered saline)
8 Enrolling by invitation Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Dietary Supplement: vitamin A
9 Completed The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
Conditions: Diabetes;   Hypertension;   Proteinuria
Interventions: Drug: Amlodipine;   Drug: Valsartan
10 Unknown  Effect of Local Administration of Morphine for Analgesia After Iliac Bone Graft Harvest
Condition: Autogenous Bone Grafts
Intervention: Drug: morphine
11 Recruiting Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients
Condition: Colitis, Ulcerative
Interventions: Drug: SB012;   Drug: Placebo
12 Unknown  Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation
Conditions: Transplantation Infection;   Kidney Diseases
Intervention:
13 Active, not recruiting The Swedish Study on Paleolithic Diet for Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Behavioral: Paleolithic diet;   Behavioral: Diabetes diet

Indicates status has not been verified in more than two years